136 related articles for article (PubMed ID: 36317990)
1. [Pharmacological chaperone therapy for the treatment of inborn errors of metabolism].
Lipiński P; Jezela-Stanek A; Tylki-Szymańska A
Postepy Biochem; 2022 Sep; 68(3):255-263. PubMed ID: 36317990
[TBL] [Abstract][Full Text] [Related]
2. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
3. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
4. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A
Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887
[TBL] [Abstract][Full Text] [Related]
5. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D
Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808
[TBL] [Abstract][Full Text] [Related]
6. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.
Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084
[TBL] [Abstract][Full Text] [Related]
7. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Migdalska-Richards A; Daly L; Bezard E; Schapira AH
Ann Neurol; 2016 Nov; 80(5):766-775. PubMed ID: 27859541
[TBL] [Abstract][Full Text] [Related]
8. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
Bendikov-Bar I; Maor G; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495
[TBL] [Abstract][Full Text] [Related]
9. Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review.
Higashi K; Sonoda Y; Kaku N; Fujii F; Yamashita F; Lee S; Tocan V; Ebihara G; Matsuoka W; Tetsuhara K; Sonoda M; Chong PF; Mushimoto Y; Kojima-Ishii K; Ishimura M; Koga Y; Fukuta A; Tsuchihashi NA; Kikuchi Y; Karashima T; Sawada T; Hotta T; Yoshimitsu M; Terazono H; Tajiri T; Nakagawa T; Sakai Y; Nakamura K; Ohga S
Mol Genet Genomic Med; 2024 Apr; 12(4):e2427. PubMed ID: 38553911
[TBL] [Abstract][Full Text] [Related]
10. Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report.
Zhang P; Zheng MF; Cui SY; Zhang W; Gao RP
Endocr Metab Immune Disord Drug Targets; 2022; 22(6):658-662. PubMed ID: 34802413
[TBL] [Abstract][Full Text] [Related]
11. Commentary on "Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease" by Zimran et al.
Goker-Alpan O
Blood Cells Mol Dis; 2013 Feb; 50(2):138-9. PubMed ID: 23083682
[No Abstract] [Full Text] [Related]
12. Identification of novel glucocerebrosidase chaperones by unexpected skeletal rearrangement reaction.
Takeda K; Watanabe T; Smith JR; Vesey D; Tiberghien N; Lewis S; Powney B; Schapira AHV; Hoshikawa T; Takle AK
Bioorg Med Chem Lett; 2023 Nov; 96():129531. PubMed ID: 37866711
[TBL] [Abstract][Full Text] [Related]
13. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Zimran A; Altarescu G; Elstein D
Blood Cells Mol Dis; 2013 Feb; 50(2):134-7. PubMed ID: 23085429
[TBL] [Abstract][Full Text] [Related]
14. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W
Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312
[TBL] [Abstract][Full Text] [Related]
15. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
[TBL] [Abstract][Full Text] [Related]
17. The additive effect on the antiepileptic treatment of ambroxol in type 3 Gaucher patient. The early observation.
Pawlinski L; Malecki MT; Kiec-Wilk B
Blood Cells Mol Dis; 2018 Feb; 68():192-193. PubMed ID: 28007403
[No Abstract] [Full Text] [Related]
18. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Silveira CRA; MacKinley J; Coleman K; Li Z; Finger E; Bartha R; Morrow SA; Wells J; Borrie M; Tirona RG; Rupar CA; Zou G; Hegele RA; Mahuran D; MacDonald P; Jenkins ME; Jog M; Pasternak SH
BMC Neurol; 2019 Feb; 19(1):20. PubMed ID: 30738426
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Insight into the Mode of Action of Acid β-Glucosidase Enhancer Ambroxol.
Pantoom S; Hules L; Schöll C; Petrosyan A; Monticelli M; Pospech J; Cubellis MV; Hermann A; Lukas J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408914
[TBL] [Abstract][Full Text] [Related]
20. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH
Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
